Pharma Q3 Preview: India Growth Offsets Revlimid Pain
Indian pharma companies face margin pressure from Revlimid patent expiry and US competition, but strong domestic sales and core business momentum may cushion the blow in Q3 FY26.
Category : Search result: Indian generic drugmakers
India's $200M Pharma Opportunity in Afghanistan
Border tensions between Afghanistan and Pakistan open a major pharmaceutical export window for India. Explore how Indian generics are filling critical shortages and strengthening regional ties.
Indian Breakthrough Improves Stability of Key Cancer Drugs
A Vadodara scholar's patented formulation for Bortezomib and Pemetrexed extends shelf life, retains 99% potency, and promises wider access in challenging climates. Read about this healthcare innovation.
Natco Pharma Sues to Revoke Novo Nordisk's Semaglutide Patent
Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Why Indian Drug Makers Challenge Global Patents
Explore the high-stakes legal battles between Indian generic manufacturers and global pharma giants. Understand the impact on drug prices, accessibility, and the evolving IP landscape in India.
Generic Drugs as Good as Brands, Cost Far Less: Study
A citizen-funded study finds generic medicines, including Jan Aushadhi, match quality of expensive brands. Experts urge trust in affordable options for better treatment adherence. #Healthcare #India
Novo Nordisk: Wegovy Price Cut to Boost India Obesity Therapy 5-7x
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
Generic Semaglutide to Create Rs 50,000 Cr Market
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Generic Semaglutide to Create Rs 50bn+ Revenue Opportunity
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
Semaglutide Patent Expiry Creates Rs 50,000 Cr Opportunity
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
Weight-loss drugs poised for takeoff, cancer care expands in 2026
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
India's 2025 Health Shift: Prevention, Generics & Digital Tools
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
Zota Health Raises ₹350 Crore, Signs Dhoni & Shetty
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Ajanta Pharma & Biocon Partner for Generic Weight Loss Drug
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
India Pharma Targets $500B, Innovation Hub by 2047
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
Govt's Data Exclusivity Push May Hit Cheap Generic Drugs
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
Jan Aushadhi Kendra rules changed: 500-meter gap enforced
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
Bangladesh Beats India to Export Weight-Loss Drugs to Emerging Markets
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Karnataka to appeal HC order on Jan Aushadi Kendras closure
Karnataka Health Minister Dinesh Gundu Rao announces state will appeal HC order quashing closure of Jan Aushadi Kendras in govt hospitals. Read the full story.
Court Rejects Ozempic Patent Extension, Boosts Generic Drug Access
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
6 Traditional Indian Egg Curries for Winter
Explore 6 flavorful egg curries from across India, perfect for the cold season. From spicy Kolhapuri to creamy Chettinad, discover regional culinary gems.
Indian Army's Sri Lanka Field Hospital Treats 1250+
Indian Army's 'Operation Sagar Bandhu' provides critical medical aid in Sri Lanka, treating over 1250 patients. A testament to India's 'Neighbourhood First' policy and strong bilateral ties.
Indian student dies after house fire injuries in US
Mohammed Abdul Arfath, an 18-year-old Indian student in Cleveland, dies from injuries sustained in a house fire. The Indian Consulate in New York is providing assistance to the family.
India Plans Global Push for Regional Cuisines as Soft Power
India launches an ambitious plan to brand its diverse regional cuisines globally through festivals, chef collaborations, and standardization, aiming to boost exports and cultural influence.
PIA Reveals Indian Icon Business Awards 2025 Winners
The Progressive Indian Alliance (PIA) has announced the distinguished winners of the Indian Icon Business Awards 2025 Special Edition, celebrating excellence across diverse sectors. Discover the leaders shaping India's economic future.
Exploring India's Diverse Regional Breakfasts
From Indori Poha to Kashmiri Kandurwan, discover the untold stories of India's regional breakfasts. A journey into culture, taste, and tradition on a plate. Explore more!
8 Indian Foods That Are Both Sweet and Savoury
Discover 8 iconic Indian foods that deliciously blur the line between sweet and savoury. Explore the culinary versatility of dishes from Dahi Vada to Malpua. Read more!
Indian Navy Day: History, Significance & Celebrations
Discover the history of Indian Navy Day on December 4, marking Operation Trident's 1971 victory. Learn how the Navy protects India's 7,500 km coastline and its vital role.
Dr Reddy's Wins Delhi HC Nod to Export Semaglutide
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
South Indian Bank Stock Hits All-Time High, Profit Jumps
South Indian Bank shares surge 80% to a record ₹41.65, driven by strong Q2 profit and improved asset quality. Mutual funds increase stake. Read for key financial insights.
Page 1 of 4